# CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)

> **NCT04205643** · PHASE3 · COMPLETED · sponsor: **Celltrion** · enrollment: 548 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **BIOLOGICAL:** CT-P13 SC (Infliximab)
- **OTHER:** Placebo SC

## Key facts

- **NCT ID:** NCT04205643
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2022-07-07
- **Final completion:** 2023-07-11
- **Target enrollment:** 548 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04205643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04205643, "CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04205643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*